Dr. Ishita Mandal

PhD (Scientist)

Ongoing project:

Alteration of BMI-1 and its associated oncogenic pathways as a prognostic marker for Gall bladder carcinoma: association with Salmonellosis and/or cholelithiasis. Funded by Sri Sri Mohanananda Cancer Fund, United Kingdom.

Publications-

• Mandal-Ghosh I, Baral R N. Generation of anti-idiotypic responses against an 85kda breast tumor associated antigen: an immunotherapeutic approach. Life sciences: an International journal (LSIJ) 2024;1 (1): 1-10.
• Mandal-Ghosh I, Dey Ghosh R, Mukhopadhyay S, Identification of Genes associated with Gall Bladder Cell Carcinogenesis: Implications in targeted therapy of Gall Bladder Cancer.

         World Journal of Gastrointestinal Oncology 2023; 15(12): 2053-

         2063

• Mandal-Ghosh I, Mukhopadhyay S, Baral RN. Neem leaf glycoprotein in reducing the gap between research and Industrial production of an Ayush Drug for Cancer treatment. Start Herb Journey from Innovation to Enterpreneurship in Herbals Proceeding Book, 2022, S.No.

            104, P-104.

•             Agarwal P, Kant K, Kaushik S, Soni A, Fernandes C L, Gowthami         R, Mandal-Ghosh I, Vaishnavi P, Lalit CK and Khanna R, Assessment of Anti-aging Efficacy of the Master Antioxidant Glutathione. International Journal of Sciences: Basic and Applied Research 2017; 33(2):257-265.
• Baral R, Sarkar K, Mandal-Ghosh I and Bose A, Neem Leaf Glycoprotein as a New Vaccine Adjuvant for Cancer Immunotherapy. Comp. Bio. Nat. Pro. 2010; Vol. 5 – Immunomodulation & Vaccine Adjuvants. Mandal (Ghosh) I, Chattopadhyay U, Baral RN, Neem leaf preparation enhances Th1 type immune response and anti-tumor immunity against tumor associated antigen. Cancer Immunity 2007; 7: 8-17.
• Haque E, Mandal I, Pal S, Baral R, Prophylactic dose of neem (Azadirachta indica) leaf preparation restricting murine tumor growth is non-toxic, hematostimulatory and immunostimulatory. Immunopharmacol Immunotoxicol 2006; 28(1): 33-50.
• Baral RN, Mandal I, Chattopadhyay U, Immunostimulatory neem leaf preparation acts an adjuvant to enhance the efficacy of poorly immunogenic B16melanoma surface antigen vaccine. Int Immunopharmacol. 2005; 5(7-8): 1343-52.